Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has been assigned a consensus rating of “Buy” from the nine ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $33.70.
ARWR has been the topic of a number of research analyst reports. TheStreet raised Arrowhead Pharmaceuticals from a “d” rating to a “c+” rating in a research note on Thursday, May 30th. Cantor Fitzgerald lowered Arrowhead Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $24.00 price objective on the stock. in a research note on Thursday, June 27th. BidaskClub raised Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, July 19th. B. Riley lifted their price objective on Arrowhead Pharmaceuticals from $32.00 to $46.00 and gave the company a “buy” rating in a research note on Monday. Finally, Piper Jaffray Companies lifted their price objective on Arrowhead Pharmaceuticals from $33.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, August 6th.
In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 27,071 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $22.00, for a total transaction of $595,562.00. Following the sale, the chief financial officer now directly owns 278,536 shares in the company, valued at approximately $6,127,792. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mauro Ferrari sold 17,756 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $27.61, for a total value of $490,243.16. Following the sale, the director now owns 1,900 shares in the company, valued at $52,459. The disclosure for this sale can be found here. Insiders have sold a total of 74,827 shares of company stock worth $1,832,205 over the last three months. 4.80% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the business. Rhumbline Advisers increased its holdings in shares of Arrowhead Pharmaceuticals by 7.2% in the 1st quarter. Rhumbline Advisers now owns 124,276 shares of the biotechnology company’s stock valued at $2,280,000 after acquiring an additional 8,313 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Arrowhead Pharmaceuticals by 812.8% in the 4th quarter. Bank of America Corp DE now owns 333,938 shares of the biotechnology company’s stock valued at $4,148,000 after acquiring an additional 380,784 shares during the last quarter. Virginia Retirement Systems ET AL bought a new stake in shares of Arrowhead Pharmaceuticals in the 1st quarter valued at approximately $391,000. Bailard Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 50.5% in the 1st quarter. Bailard Inc. now owns 165,600 shares of the biotechnology company’s stock valued at $3,039,000 after acquiring an additional 55,600 shares during the last quarter. Finally, Strs Ohio increased its holdings in shares of Arrowhead Pharmaceuticals by 109.5% in the 2nd quarter. Strs Ohio now owns 26,400 shares of the biotechnology company’s stock valued at $699,000 after acquiring an additional 13,800 shares during the last quarter. Institutional investors own 73.52% of the company’s stock.
Arrowhead Pharmaceuticals stock traded up $2.53 during midday trading on Wednesday, reaching $33.72. 1,691,824 shares of the company were exchanged, compared to its average volume of 1,737,730. The company has a market capitalization of $2.77 billion, a price-to-earnings ratio of -51.88 and a beta of 1.59. The firm’s 50-day simple moving average is $28.34 and its 200-day simple moving average is $22.25. Arrowhead Pharmaceuticals has a 1 year low of $10.41 and a 1 year high of $34.02.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.34 by ($0.13). Arrowhead Pharmaceuticals had a return on equity of 26.27% and a net margin of 33.28%. The business had revenue of $42.70 million during the quarter, compared to analyst estimates of $59.05 million. On average, sell-side analysts expect that Arrowhead Pharmaceuticals will post 0.73 earnings per share for the current fiscal year.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Featured Story: Different Options Trading Strategies
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.